[Why&Next] Novo Targets 'Women Expansion' vs Lilly Focuses on 'Rebound Prevention'... Which Strategy Will Korean Obesity Drugs Choose?
Hanmi Focuses on Expanding Indications
D&D Pharmatech, Ildong, and Yuhan Prioritize Convenience
Weight Loss Alone Has Its Limits
Differentiation Is Key for Latecomer Korean Companies
As the first domestically developed glucagon-like peptide-1 (GLP-1) obesity treatment is set to be released in the second half of this year, attention is focused on the strategic choices of Korean pharmaceutical companies. The global obesity drug market has become divided between Novo Nordisk (hereafter Novo), which is expanding its pool of new patients, and Eli Lilly (hereafter Lilly), which is focused on encouraging long-term use among existing patients. There is growing interest in how latecomer Korean companies will find their own points of differentiation between these two approaches.
According to the global and domestic bio industry on May 22, at the European Congress on Obesity (ECO 2026) held in Istanbul, Turkey from May 12 to 15, Novo and Lilly each presented starkly contrasting strategies, drawing significant attention in the obesity treatment market. Novo concentrated on expanding indications to new patient groups, such as postmenopausal women, while Lilly focused on encouraging long-term use among existing patients to prevent them from discontinuing the medication.
Novo presented a reanalysis of clinical data for Wegovy (active ingredient: semaglutide) by menopausal stage. The company re-examined the obesity indication clinical trial 'STEP UP' and the cardiovascular disease indication trial 'SELECT' by menopausal stages. According to Novo, both pre- and post-menopausal women experienced about a 20% reduction in body weight, with the most pronounced weight loss and cardiovascular protection observed in women approaching menopause. In real-world studies tracking menopausal women, a reduction in occurrences of migraines and depression was also observed.
Industry insiders see Novo's release of these findings as a move to attract women, who previously had less reason to use obesity medications, as a new source of demand. Menopause is a period marked by hormonal changes that often lead to weight gain and increased cardiovascular risk, but this group has been relatively neglected in obesity research and prescriptions. By targeting this gap, Novo has presented new evidence supporting the use of Wegovy in these patients.
Lilly, on the other hand, has set its sights on existing patients. The company announced results from two clinical studies that directly addressed the major drawbacks of GLP-1 obesity drugs: the rebound effect and the burden of having to take injections for life. The findings were recently published simultaneously in the international journals 'The Lancet' and 'Nature Medicine.'
The studies showed that patients who maintained their dosage after losing weight with the injectable drug Zepbound (active ingredient: tirzepatide) were able to maintain their weight loss. Even patients who initially lost weight with Wegovy and then switched to Lilly's oral drug Orforglipron (brand name: PounDayo) were able to sustain most of the weight loss over one year.
This research is seen as reflecting Lilly's strategy to ensure patients who have started treatment do not discontinue, effectively locking in existing patients as long-term customers. By providing options to reduce dosage or switch to oral formulations, the company aims to prevent patient drop-off and even attract patients who had previously used competitors' drugs.
Lilly is also accelerating efforts to enhance weight loss itself. In the phase 3 clinical trial for its next-generation obesity drug Retatrutide, results released on May 21 showed that the highest-dose group experienced an average weight reduction of 28.3% over 80 weeks. Of these, 45.3% achieved weight loss exceeding 30%, a level comparable to metabolic surgery. The new drug targets one additional hormone compared to Wegovy and Mounjaro, resulting in greater efficacy.
Hanmi pursues 'expansion,' while D&D Pharmatech, Ildong, and Yuhan focus on 'convenience'... Diverging paths for Korean drugs
As strategies for obesity treatment development enter a new phase, there is mounting interest in the choices of latecomer Korean companies.
Industry leader Hanmi Pharmaceutical is taking the path of expanding indications. The company intends to develop its first GLP-1 obesity drug, Efeglenatide, not simply as a weight-loss medication, but as an integrated metabolic disease treatment covering cardiovascular and kidney protection as well as diabetes therapy.
D&D Pharmatech, Ildong Pharmaceutical, and Yuhan Corporation are focusing on improving convenience of administration. Their strategy is to make it easier for patients to take the medication for longer periods, thereby preventing treatment discontinuation. D&D Pharmatech has licensed out a candidate substance to U.S.-based Metsera, leveraging its oral administration platform that converts the predominantly injectable GLP-1 medication into an oral form. Ildong Pharmaceutical also confirmed significant weight loss effects in early clinical trials of its oral GLP-1 candidate. Yuhan Corporation, in partnership with Inventage Lab, is developing a long-acting injection that reduces the frequency from once a week to once a month and is moving towards clinical trials.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Some experts suggest that the success of Korean-made obesity drugs may depend more on price and insurance coverage than efficacy. One industry insider said, "Because obesity drugs are mostly not reimbursed, patients pay hundreds of thousands of won each month. If domestic drugs can lower the price and help patients stay on treatment, they could address the drop-out issue that global drugs have not solved."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.